ClinicalTrials.gg

Program

sutezolid

Also written as “PNU-100480”, “BIA 5-1058 and Furosemide” and “Treatment C”.

Its studies are mostly in Tuberculosis · Pulmonary Arterial Hypertension · Diabetes Mellitus, Type 2, led by 3 companies.

Furthest: phase 2, since Oct 19, 20105 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sequella30 open or runningphase 2since Oct 19, 2010Mar 27, 2009none ahead
AJU Pharm10 open or runningphase 1since Jul 12, 2021Jul 12, 2021none ahead
Bial - Portela C10 open or runningphase 1since Sep 8, 2025Sep 8, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2009First study: phase 1 study in TuberculosisNew to SequellaSequella · NCT00871949 · 19 enrolled · United States
  2. Oct 6, 2009Phase 1 study in TuberculosisSequella · NCT00990990 · 59 enrolled · United States
  3. Oct 19, 2010Phase 2 study in TuberculosisSequella · NCT01225640 · 59 enrolled · South Africa
  4. Jul 12, 2021AJU Pharm's first study: phase 1 study in Diabetes Mellitus, Type 2New to AJU PharmAJU Pharm · NCT04970940 · 30 enrolled · Korea, Republic of
  5. Sep 8, 2025Bial - Portela C's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Bial - Portela CBial - Portela C · NCT07173738 · 44 enrolled · United Kingdom

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“70S ribosome inhibitor”ChEMBL 37, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07173738Pulmonary Arterial Hypertension · United Kingdom1CompletedBial - Portela CSep 7, 201844
NCT04970940Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedAJU PharmOct 7, 202030
NCT01225640Tuberculosis · South Africa2CompletedSequellaDec 201159
NCT00990990Tuberculosis · United States1CompletedSequellaMay 201059
NCT00871949Tuberculosis · United States1CompletedSequellaAug 200919

How it is read

Names in the registry

  • “PNU-100480”, 23 entries
  • “BIA 5-1058 and Furosemide”, 1 entry
  • “Treatment C”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.